Skip to main content
Pixium Vision logo

Pixium Vision — Investor Relations & Filings

Ticker · ALPIX ISIN · FR001400JX97 LEI · 96950046OPLRLKKEOO08 PA Manufacturing
Open in API
Filings indexed 440 across all filing types
Latest filing 2015-04-22 Regulatory Filings
Country FR France
Listing PA ALPIX

About Pixium Vision

https://www.pixium-vision.com/

Pixium Vision was a bioelectronics company that developed bionic vision systems to restore partial sight for patients with retinal diseases. Its core technology, the PRIMA System, is a photovoltaic subretinal implant designed to treat vision loss from advanced atrophic dry age-related macular degeneration (dry AMD). The system uses specialized glasses to project near-infrared light onto the implant, which converts the light into electrical signals to stimulate retinal cells and create a form of prosthetic vision. The company's assets, including the PRIMA technology and its ongoing European pivotal trial (PRIMAvera), were acquired by Science Corporation in late 2023. The trials and device manufacturing are now sponsored by La Science SAS.

Recent filings

Filing Released Lang Actions
Communiqués en période d’offre / Autres communiqués
Regulatory Filings Classification · 99% confidence The document is a press release dated April 22, 2015, announcing a visit from a government minister (Madame Marisol Touraine) to the company's facility to observe progress on their vision restoration system (IRIS®). It discusses clinical trials, future product plans (PRIMA), and includes standard contact and forward-looking statements. This type of announcement, which communicates general corporate news, progress updates, and executive/product milestones outside of mandatory financial reporting cycles (like 10-K, ER, or IR), best fits the general 'Regulatory Filings' or 'Miscellaneous' category, as it is not a specific financial report, management discussion, director dealing, or capital change notice. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback category) is the most appropriate classification for a general corporate press release of this nature.
2015-04-22 French
Communications during bidding periods / Other releases
Regulatory Filings Classification · 99% confidence The document is a dated announcement (April 22, 2015) detailing a visit from a French Health Minister and providing updates on the company's clinical trials (IRIS® and PRIMA systems) and expected commercialization timelines. It includes quotes from the CEO and contact information for investor/press relations. This structure is characteristic of a press release or news announcement regarding company progress, rather than a formal regulatory filing like a 10-K, IR, or a specific financial report. Since it is an announcement of company news and progress, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory/news announcement, or potentially an Earnings Release (ER) if it contained financial results, but it focuses more on operational/clinical milestones. Given the content is a general corporate update/news release, RNS is the most appropriate fallback for non-standard announcements, although it shares characteristics with an ER/MDA. Since it is not a formal financial report or a specific defined announcement (like DIV or DIRS), RNS is the best fit.
2015-04-22 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 90% confidence The document is a press release dated April 22, 2015, announcing that Pixium Vision's research partner, Stanford University, will present pre-clinical results of the PRIMA implant at an IEEE/EMBS conference. It details scientific findings (restoration of visual acuity, preservation of inner retina) related to a medical device. This is not a formal regulatory filing like a 10-K, 10-Q (IR), or an official earnings release (ER). It is an announcement about scientific progress and presentation of data, which falls under general investor/corporate communication. Since it is a press release detailing company progress and technology updates, and does not fit the specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), it is best classified as a general Regulatory Filing (RNS) as a catch-all for non-standard announcements, or potentially Investor Presentation (IP) if it were the presentation itself, but here it is an announcement *about* a presentation. Given the context of a press release announcing research findings, RNS is the most appropriate general category for non-standard corporate news.
2015-04-22 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated April 22, 2015, announcing that Pixium Vision's research partner, Stanford University, will present preclinical results for the PRIMA retinal implant at the 7th IEEE EMBS Neural Engineering conference. The text details scientific findings ('Restauration photovoltaïque d'une acuité visuelle élevée chez des rats atteints de dégénérescence rétinienne') and includes standard sections like contacts and forward-looking statements typical of corporate news releases. This content is an announcement of research findings being presented at a conference, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). It is a general corporate announcement regarding scientific progress, which fits best under the general 'Regulatory Filings' (RNS) category as a fallback, or potentially an Investor Presentation (IP) if it were the presentation itself, but since it's an announcement *about* a presentation, RNS is the most appropriate general classification for non-standard corporate news.
2015-04-22 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 98% confidence The document is a press release dated April 13, 2015, announcing that Pixium Vision has reinforced its intellectual property by having a patent maintained in Europe following an opposition procedure and receiving a new patent grant in the United States concerning its IRIS® system. The content focuses entirely on patent maintenance, grant decisions, and intellectual property portfolio strength. This subject matter aligns best with the category for Intellectual Property filings or announcements related to proprietary technology protection. Given the specific options, 'Intellectual Property' (IP) is the most fitting classification, as it directly relates to patent grants and maintenance decisions, which are key aspects of IP management.
2015-04-13 French
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 95% confidence The document is a press release dated April 13, 2015, announcing that Pixium Vision has strengthened its intellectual property by having a patent maintained in Europe following an opposition and having a corresponding patent granted in the US. The content focuses on legal/IP developments (patents) rather than financial results, management changes, or standard regulatory filings like 10-K or ER. Since the document details specific legal/IP actions and outcomes, it does not fit neatly into the primary financial categories. It is not a standard regulatory filing (RNS) but a specific announcement about legal/IP matters. Given the available options, 'Legal Proceedings Report' (LTR) is the closest fit, as patent maintenance/grant/opposition involves legal and regulatory processes concerning intellectual property rights, which often fall under the broader scope of legal updates, even if it's positive news rather than a lawsuit report.
2015-04-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.